\
&
Contact us
Published on | 4 years ago
Programmes ICT NMBP HealthINNO4COV-19 OPEN CALL - Boosting Innovation for COVID-19 Diagnostic, Prevention and Surveillance
Are you working for a company active in healthcare, medicine, biotech, biopharma, and/or IT-related topics (e.g. robotics, automation, electronics, nanotech, etc)? Then have a look at this accessible funding scheme (up to 100k€ subsidy).
Submission deadlines in November 2020, March 2021 and May 2021.
INNO4COV-19 at a Glance
Create a “lab-to-fab” platform and collaboration resource to enable companies and reference laboratories to develop and implement innovative technologies to fight COVID-19.
Website: www.inno4cov19.eu
The INNO4COV-19 Project aims to support the full development to market uptake of technologies at TRL6-7 or higher. It Provides funding to third parties to archive the desiderated objectives.
Eligibility criteria
What they offer
Key dates
The applications will be considered in three different rounds.
More information on the website of the call: www.inno4cov19.eu/open-call
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.